Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level

Helicobacter pylori infection is the major cause of gastric cancer, and removal of H. pylori infection from a population could theoretically decrease the number of cases by about 89%. However, in real‐life settings, few studies have reported the effect of screening and treating this pathogen in population‐based programs. This is mainly because of the lack of an adequate infrastructure for delivery of systematic screening services to asymptomatic individuals, the lack of standardization to ensure that each subject receives the correct diagnostic testing and antibiotic treatment, and limited resources. We illustrate our method of implementing two population‐based screen‐and‐treat programs in Taiwan, where the epidemiological characteristics of disease burden have changed from the traditionally Eastern pattern towards that of the Western countries. Our first example is a high‐risk population that resides on an offshore island, in which a strategy of mass eradication of H. pylori was applied. The other example is an intermediate‐risk population, which is representative of the general average‐risk population, in which there is integration of the screen‐and‐treat method with the established framework of colorectal cancer screening using the fecal‐occult blood test. The information provided here may be useful for integration of gastric cancer prevention measures into the healthcare priorities of populations with different gastric cancer risks, such as those with limited resources.